Actively Recruiting

Phase Not Applicable
Age: 18Years - 65Years
FEMALE
NCT07009327

Efficacy and Safety of Photodynamic Therapy for CIN3

Led by Peking University Third Hospital · Updated on 2025-06-06

100

Participants Needed

1

Research Sites

313 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

To investigate the efficacy and safety of photodynamic therapy (20% 5-amino-ketovalerate 630nm red light) in the treatment of cervical intraepithelial neoplasia 3(CIN 3)in women in the real world

CONDITIONS

Official Title

Efficacy and Safety of Photodynamic Therapy for CIN3

Who Can Participate

Age: 18Years - 65Years
FEMALE

Eligibility Criteria

Eligible

You may qualify if you...

  • CIN3 diagnosis requiring photodynamic therapy
  • Type 1 or 2 transformation area confirmed by colposcopy
  • Lesion boundary is completely visible
  • Endocervical curettage (ECC) does not show high-grade lesions
Not Eligible

You will not qualify if you...

  • Presence or suspicion of cancer
  • TCT test showing high-grade squamous intraepithelial lesion (HSIL)
  • Lesion involving glands
  • History of porphyria or suspected allergy to red and blue light
  • Severe medical comorbidities

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Peking Unniversity Third Hospital

Beijing, China, 100191

Actively Recruiting

Loading map...

Research Team

Q

Qin Han

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SINGLE_GROUP

Primary Purpose

TREATMENT

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here